Relevant bibliographies by topics / Immunoglobulin G N-Glycome

Academic literature on the topic 'Immunoglobulin G N-Glycome'

Author: Grafiati
Published: 23 August 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immunoglobulin G N-Glycome.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immunoglobulin G N-Glycome"

1

Singh, Sunny S., Annemieke Naber, Viktoria Dotz, Emma Schoep, Elham Memarian, Roderick C. Slieker, Petra J. M. Elders, et al. "Metformin and statin use associate with plasma protein N-glycosylation in people with type 2 diabetes." BMJ Open Diabetes Research & Care 8, no. 1 (July 2020): e001230. http://dx.doi.org/10.1136/bmjdrc-2020-001230.

Full text
Abstract:
IntroductionRecent studies revealed N-glycosylation signatures of type 2 diabetes, inflammation and cardiovascular risk factors. Most people with diabetes use medication to reduce cardiovascular risk. The association of these medications with the plasma N-glycome is largely unknown. We investigated the associations of metformin, statin, ACE inhibitor/angiotensin II receptor blocker (ARB), sulfonylurea (SU) derivatives and insulin use with the total plasma N-glycome in type 2 diabetes.Research design and methodsAfter enzymatic release from glycoproteins, N-glycans were measured by matrix-assisted laser desorption/ionization mass spectrometry in the DiaGene (n=1815) and Hoorn Diabetes Care System (n=1518) cohorts. Multiple linear regression was used to investigate associations with medication, adjusted for clinical characteristics. Results were meta-analyzed and corrected for multiple comparisons.ResultsMetformin and statins were associated with decreased fucosylation and increased galactosylation and sialylation in glycans unrelated to immunoglobulin G. Bisection was increased within diantennary fucosylated non-sialylated glycans, but decreased within diantennary fucosylated sialylated glycans. Only few glycans were associated with ACE inhibitor/ARBs, while none associated with insulin and SU derivative use.ConclusionsWe conclude that metformin and statins associate with a total plasma N-glycome signature in type 2 diabetes. Further studies are needed to determine the causality of these relations, and future N-glycomic research should consider medication a potential confounder.
APA, Harvard, Vancouver, ISO, and other styles
2

Lin, Sihan, You Wang, Xinran Wang, Bin Yan, Weihua Lou, and Wen Di. "Serum immunoglobulin G N-glycome: a potential biomarker in endometrial cancer." Annals of Translational Medicine 8, no. 12 (June 2020): 748. http://dx.doi.org/10.21037/atm-20-3504.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Simunovic, Jelena, Marija Vilaj, Irena Trbojevic-Akmacic, Ana Momcilovic, Frano Vuckovic, Ivan Gudelj, Julija Juric, Natali Nakic, Gordan Lauc, and Marija Pezer. "Comprehensive N-glycosylation analysis of immunoglobulin G from dried blood spots." Glycobiology 29, no. 12 (May 30, 2019): 817–21. http://dx.doi.org/10.1093/glycob/cwz061.

Full text
Abstract:
Abstract Immunoglobulin G (IgG) glycans are emerging as a new putative biomarker for biological age and different diseases, requiring a robust workflow for IgG glycome analysis, ideally beginning with a simple and undemanding sampling procedure. Here, we report the first comprehensive study on total N-glycans of IgG isolated from dried blood spots (DBSs), which was performed in a high-throughput mode. We compared the IgG N-glycan profiles originating from DBS with those originating from plasma, compared different media for DBS collection, evaluated analytical variation and assessed IgG N-glycan profile stability for different storage conditions. In conclusion, we show that DBSs are a good and stable source material for a robust IgG N-glycan analysis by ultra-performance liquid chromatography, suitable for blood sampling in conditions where no trained personnel and necessary laboratory equipment are available.
APA, Harvard, Vancouver, ISO, and other styles
4

Hanić, Maja, Frano Vučković, Helena Deriš, Claire Bewshea, Simeng Lin, James R. Goodhand, Tariq Ahmad, Irena Trbojević-Akmačić, Nicholas A. Kennedy, and Gordan Lauc. "Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease." Biomolecules 13, no. 6 (June 7, 2023): 954. http://dx.doi.org/10.3390/biom13060954.

Full text
Abstract:
Crohn’s disease (CD) is a chronic inflammation of the digestive tract that significantly impairs patients’ quality of life and well-being. Anti-TNF biologicals revolutionised the treatment of CD, yet many patients do not adequately respond to such therapy. Previous studies have demonstrated a pro-inflammatory pattern in the composition of CD patients’ immunoglobulin G (IgG) N-glycome compared to healthy individuals. Here, we utilised the high-throughput UHPLC method for N-glycan analysis to explore the longitudinal effect of the anti-TNF drugs infliximab and adalimumab on N-glycome composition of total serum IgG in 198 patients, as well as the predictive potential of IgG N-glycans at baseline to detect primary non-responders to anti-TNF therapy in 1315 patients. We discovered a significant decrease in IgG agalactosylation and an increase in monogalactosylation, digalactosylation and sialylation during the 14 weeks of anti-TNF treatment, regardless of therapy response, all of which suggested a diminished inflammatory environment in CD patients treated with anti-TNF therapy. Furthermore, we observed that IgG N-glycome might contain certain information regarding the anti-TNF therapy outcome before initiating the treatment. However, it is impossible to predict future primary non-responders to anti-TNF therapy based solely on IgG N-glycome composition at baseline.
APA, Harvard, Vancouver, ISO, and other styles
5

Radovani, Barbara, Frano Vučković, Aldo P. Maggioni, Ele Ferrannini, Gordan Lauc, and Ivan Gudelj. "IgG N-Glycosylation Is Altered in Coronary Artery Disease." Biomolecules 13, no. 2 (February 16, 2023): 375. http://dx.doi.org/10.3390/biom13020375.

Full text
Abstract:
Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques. Our aim was to determine whether the N-glycome of immunoglobulin G (IgG) is associated with CAD, as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response in CAD. Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD−). The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR). Sex-stratified analysis of 316 CAD− and 156 CAD+ cases revealed differences in IgG N-glycome composition. The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD. The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
APA, Harvard, Vancouver, ISO, and other styles
6

Font, Guillaume, Marie-Laure Walet-Balieu, Marie Petit, Carole Burel, Maud Maho-Vaillant, Vivien Hébert, Philippe Chan, et al. "IgG N-Glycosylation from Patients with Pemphigus Treated with Rituximab." Biomedicines 10, no. 8 (July 22, 2022): 1774. http://dx.doi.org/10.3390/biomedicines10081774.

Full text
Abstract:
Pemphigus is a life-threatening auto-immune blistering disease of the skin and mucous membrane that is caused by the production of auto-antibodies (auto-Abs) directed against adhesion proteins: desmoglein 1 and 3. We demonstrated in the “Ritux3” trial, the high efficacy of rituximab, an anti-CD20 recombinant monoclonal antibody, as the first-line treatment for pemphigus. However, 25% of patients relapsed during the six-month period after rituximab treatment. These early relapses were associated with a lower decrease in anti-desmoglein auto-Abs after the initial cycle of rituximab. The N-glycosylation of immunoglobulin-G (IgG) can affect their affinity for Fc receptors and their serum half-life. We hypothesized that the extended half-life of Abs could be related to modifications of IgG N-glycans. The IgG N-glycome from pemphigus patients and its evolution under rituximab treatment were analyzed. Pemphigus patients presented a different IgG N-glycome than healthy donors, with less galactosylated, sialylated N-glycans, as well as a lower level of N-glycans bearing an additional N-acetylglucosamine. IgG N-glycome from patients who achieved clinical remission was not different to the one observed at baseline. Moreover, our study did not identify the N-glycans profile as discriminating between relapsing and non-relapsing patients. We report that pemphigus patients present a specific IgG N-glycome. The changes observed in these patients could be a biomarker of autoimmunity susceptibility rather than a sign of inflammation.
APA, Harvard, Vancouver, ISO, and other styles
7

Flevaris, Konstantinos, and Cleo Kontoravdi. "Immunoglobulin G N-glycan Biomarkers for Autoimmune Diseases: Current State and a Glycoinformatics Perspective." International Journal of Molecular Sciences 23, no. 9 (May 6, 2022): 5180. http://dx.doi.org/10.3390/ijms23095180.

Full text
Abstract:
The effective treatment of autoimmune disorders can greatly benefit from disease-specific biomarkers that are functionally involved in immune system regulation and can be collected through minimally invasive procedures. In this regard, human serum IgG N-glycans are promising for uncovering disease predisposition and monitoring progression, and for the identification of specific molecular targets for advanced therapies. In particular, the IgG N-glycome in diseased tissues is considered to be disease-dependent; thus, specific glycan structures may be involved in the pathophysiology of autoimmune diseases. This study provides a critical overview of the literature on human IgG N-glycomics, with a focus on the identification of disease-specific glycan alterations. In order to expedite the establishment of clinically-relevant N-glycan biomarkers, the employment of advanced computational tools for the interpretation of clinical data and their relationship with the underlying molecular mechanisms may be critical. Glycoinformatics tools, including artificial intelligence and systems glycobiology approaches, are reviewed for their potential to provide insight into patient stratification and disease etiology. Challenges in the integration of such glycoinformatics approaches in N-glycan biomarker research are critically discussed.
APA, Harvard, Vancouver, ISO, and other styles
8

Blomme, Bram, Christophe Van Steenkiste, Paola Grassi, Stuart M. Haslam, Anne Dell, Nico Callewaert, and Hans Van Vlierberghe. "Alterations of serum protein N-glycosylation in two mouse models of chronic liver disease are hepatocyte and not B cell driven." American Journal of Physiology-Gastrointestinal and Liver Physiology 300, no. 5 (May 2011): G833—G842. http://dx.doi.org/10.1152/ajpgi.00228.2010.

Full text
Abstract:
N-glycosylation of immunoglobulin G (IgG) has an important impact on the modification of the total serum N-glycome in chronic liver patients. Our aim was to determine the role and magnitude of the alterations in which hepatocytes and B cells are involved in two mouse models of chronic liver disease. Common bile duct ligation (CBDL) and subcutaneous injections with CCl4 were induced in B cell-deficient and wild-type (WT) mice. IgG depletion was performed with beads covered with protein A/G and the depletions were evaluated by SDS-PAGE and Western blot analysis. N-glycan analysis was performed by improved DSA-FACE technology. Structural analysis of the mouse serum N-glycans was performed by exoglycosidase digests and MALDI-TOF mass spectrometry of permethylated glycans. The alterations seen in B cell-deficient mice closely resembled the alterations in WT mice, in both the CBDL and the CCl4 models. N-glycan analysis of the IgG fraction in both mouse models revealed different changes compared with humans. Overall, the impact of IgG glycosylation on total serum glycosylation was marginal. Interestingly, the amount of fibrosis present in CBDL B cell-deficient mice was significantly increased compared with CBDL WT mice, whereas the opposite was true for the CCl4 model as determined by Sirius red staining. However, this had no major effect on the alteration of N-glycosylation of serum proteins. Alterations of total serum N-glycome in mouse models of chronic liver disease are hepatocyte-driven. Undergalactosylation of IgG is not present in mouse models of chronic liver disease.
APA, Harvard, Vancouver, ISO, and other styles
9

Suhre, Karsten, Irena Trbojević-Akmačić, Ivo Ugrina, Dennis Mook-Kanamori, Tim Spector, Johannes Graumann, Gordan Lauc, and Mario Falchi. "Fine-Mapping of the Human Blood Plasma N-Glycome onto Its Proteome." Metabolites 9, no. 7 (June 26, 2019): 122. http://dx.doi.org/10.3390/metabo9070122.

Full text
Abstract:
Most human proteins are glycosylated. Attachment of complex oligosaccharides to the polypeptide part of these proteins is an integral part of their structure and function and plays a central role in many complex disorders. One approach towards deciphering this human glycan code is to study natural variation in experimentally well characterized samples and cohorts. High-throughput capable large-scale methods that allow for the comprehensive determination of blood circulating proteins and their glycans have been recently developed, but so far, no study has investigated the link between both traits. Here we map for the first time the blood plasma proteome to its matching N-glycome by correlating the levels of 1116 blood circulating proteins with 113 N-glycan traits, determined in 344 samples from individuals of Arab, South-Asian, and Filipino descent, and then replicate our findings in 46 subjects of European ancestry. We report protein-specific N-glycosylation patterns, including a correlation of core fucosylated structures with immunoglobulin G (IgG) levels, and of trisialylated, trigalactosylated, and triantennary structures with heparin cofactor 2 (SERPIND2). Our study reveals a detailed picture of protein N-glycosylation and suggests new avenues for the investigation of its role and function in the associated complex disorders.
APA, Harvard, Vancouver, ISO, and other styles
10

Šimunić-Briški, Nina, Robert Zekić, Vedran Dukarić, Mateja Očić, Azra Frkatović-Hodžić, Helena Deriš, Gordan Lauc, and Damir Knjaz. "Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population." Biomolecules 13, no. 5 (April 27, 2023): 762. http://dx.doi.org/10.3390/biom13050762.

Full text
Abstract:
Regular exercise improves health, modulating the immune system and impacting inflammatory status. Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81). Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention. After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation. Exercise intervention induced significant changes in IgG N-glycome composition. We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10−4, 2.41 × 10−25, 1.51 × 10−21 and 3.38 × 10−30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10−12, 7.61 × 10−9 and 1.09 × 10−28, respectively). We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10−16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health. Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immunoglobulin G N-Glycome"

1

Russell, Alyce. "Quantifying the heterogeneity of the immunoglobulin G N-Glycome in an ageing Australian population: The Busselton Healthy Ageing Study." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2020. https://ro.ecu.edu.au/theses/2290.

Full text
Abstract:
The use of immunoglobulin G N-glycomics to study chronic non-communicable disorders and other complex phenotypes emerged following the Human Genome Project. The consortium discovered that most phenotypes were too complex to be explained by genetics alone. Thus, the biological importance of epigenetics was recognised; heritable modifications to gene expression rather than the genome itself. Nglycosylation is a form of epigenetic regulation known as a post-translational modification. It stabilises the immunoglobulin G structure and alters downstream responses elicited by the antibody and is extensively studied as a candidate biomarker in the post-genomic era. The N-glycosylation of immunoglobulin G itself is complex, with glycosyltransferases and glycosylhydrolases influencing the biosynthesis of the branching structures. Moreover, altered N-glycosylation is associated with an array of phenotypes. Our research team considers the N-glycome as an interphenotype of subclinical health status; an amalgamation of genetic predisposition, environmental exposure and health behaviours over the life-course. This underscores the value of the immunoglobulin G N-glycome in the shift towards predictive, preventive and personalised medicine. However, there is still considerable heterogeneity even among individuals with the same disorder, which warrants further investigation to improve precision of the biomarker. This thesis aimed to determine the degree the underlying genome and clinical factors explain the heterogeneity of the immunoglobulin G N-glycome. I used a subset of the cross-sectional population-based Busselton Healthy Ageing Study (n=637, 54.0% female, 46.2 to 68.3 years of age). The participants represent a highly homogenous population (99% identify as Caucasian with Caucasian parents), and all noninstitutionalised ‘Baby-boomers’ (adults born between 1946 and 1964) listed on the electoral roll in the City of Busselton between 2010 and 2016 were eligible to participate. Three studies were designed to address the thesis aim. Firstly, previous IgG-related genetic polymorphisms were successfully validated using association studies of the N-glycan features. Secondly, next-generation sequencing of leucocyte mRNA was modelled with the N-glycome. Differentially expressed genes were identified, as well as the implementation of a multivariate model to integrate the ‘omics datasets. Finally, clinical factors and health behaviours were modelled using various statistics, extending on previous research. Collectively, however, the three studies evidenced potential utility of the immunoglobulin G N-glycome in identifying cardiometabolic disorders and associated risk factors. A polymorphism with genome-wide significance had pleiotropy to type 2 diabetes mellitus. Additionally, the clinical studies correlated cardiometabolic risk factors (central adiposity, blood pressure, C-reactive protein, triglycerides, fasting blood glucose and insulin) as well as the health behaviours excessive alcohol consumption and current smoking status (both associated with increased risk of cardiometabolic disorders) to an increase in pro-inflammatory immunoglobulin G glycoforms, thus potentiating involvement of immunoglobulin G in the pathophysiology of these phenotypes. Overall, this data-driven thesis identified several factors explaining immunoglobulin G N-glycome heterogeneity. These should be considered in subsequent translational research, to improve the precision of this complex biomarker when stratifying populations of interest.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immunoglobulin G N-Glycome"

1

"Statistical relations between N-glycome of circulating immunoglobuline G and total plasma N-Glycome." In Bioinformatics of Genome Regulation and Structure/ Systems Biology. institute of cytology and genetics siberian branch of the russian academy of science, Novosibirsk State University, 2020. http://dx.doi.org/10.18699/bgrs/sb-2020-010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immunoglobulin G N-Glycome' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography